GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
GSK's total debt was £17.72B at Dec 31, 2025. For fiscal 2025 it was £17.72B, up 4.3% from the year before. The highest annual figure on record is £30.51B in fiscal 2019.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £17.72B | +4.3% |
| FY2024 | Dec 31, 2024 | £16.99B | -5.7% |
| FY2023 | Dec 31, 2023 | £18.02B | -14.1% |
| FY2022 | Dec 31, 2022 | £20.99B | -13.2% |
| FY2021 | Dec 31, 2021 | £24.17B | -11.0% |
| FY2020 | Dec 31, 2020 | £27.15B | -11.0% |
| FY2019 | Dec 31, 2019 | £30.51B | +17.1% |
| FY2018 | Dec 31, 2018 | £26.06B | +52.5% |
| FY2017 | Dec 31, 2017 | £17.09B | -9.1% |
| FY2016 | Dec 31, 2016 | £18.79B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | £17.72B | -26.7% |
| Q4 FY2024 | Dec 31, 2024 | £16.99B | -37.4% |
| Q4 FY2023 | Dec 31, 2023 | £18.02B | -40.9% |
| Q4 FY2022 | Dec 31, 2022 | £20.99B | -19.5% |
| Q4 FY2021 | Dec 31, 2021 | £24.17B | +41.5% |
| Q4 FY2020 | Dec 31, 2020 | £27.15B | +44.5% |
| Q4 FY2019 | Dec 31, 2019 | £30.51B | – |
| Q4 FY2018 | Dec 31, 2018 | £26.06B | – |
| Q4 FY2017 | Dec 31, 2017 | £17.09B | – |
| Q4 FY2016 | Dec 31, 2016 | £18.79B | – |